New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Allogene Therapeutics, Inc. (ALLO) vs Faeth Therapeutics, Inc. (FTH)

Allogene Therapeutics, Inc. and Faeth Therapeutics, Inc. are both Biotechnology companies. Allogene Therapeutics, Inc. and Faeth Therapeutics, Inc. are of similar size ($231.1M and $224.6M). Across the 9 metrics below, Allogene Therapeutics, Inc. leads on 5 and Faeth Therapeutics, Inc. on 4.

Valuation

Metric ALLO FTH Biotechnology median
P/E n/m n/m 8.49
P/S 45.61 — 8.56
P/B 0.55 1.27 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.43 n/m 0.69
EV/Sales (16.66) — 8.00
Earnings yield (101.61%) (1,759.44%) (35.81%)
Free cash flow yield (50.71%) (21.23%) (25.41%)

Profitability

Metric ALLO FTH Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (342,700.00%) — 0.00%
Net margin (335,973.56%) — 0.00%
Free cash flow margin (261,473.56%) — 0.00%
Return on equity (49.29%) (229.61%) (51.58%)
Return on assets (36.69%) (204.67%) (45.91%)
Return on invested capital (119.37%) 0.00% 0.00%

Growth

Metric ALLO FTH Biotechnology median
Revenue growth (TTM) (30.40%) — 7.20%
EPS growth (last fiscal year) 34.09% 30.33% 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ALLO FTH Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.79 16.12 4.79
Net debt to EBITDA 1.24 0.96 1.01

Dividend

Metric ALLO FTH Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALLO FTH Biotechnology median
Market cap 231.06m 224.58m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack